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COX-2 mRNA and PGE2
Original Article
Purpose
83b1 is a novel quinoline derivative that has been shown to inhibit cancer growth in human
esophageal squamous cell carcinoma (ESCC). This study was conducted to comprehensively
evaluate the cytotoxic effects of 83b1 on a series of ESCC cell lines and investigate the
mechanisms by which 83b1 suppresses cancer growth based on molecular docking analy-
sis.
Materials and Methods
A series of ESCC and nontumor immortalized cell lines were exposed to 83b1 and cisplatin
(CDDP) in a dose-dependent manner, and the cytotoxicity was examined by a MTS assay
kit. Prediction of the molecular targets of 83b1 was conducted by molecular docking analy-
sis. Expression of cyclooxygenase 2 (COX-2) mRNA and COX-2–derived prostaglandin E2
(PGE2) were measured by quantitative real-time polymerase chain reaction and enzyme-
linked immuno-sorbent assay, respectively. In vivo anti-tumor effect was determined using
a nude mice xenografted model transplanted with an ESCC cell line, KYSE-450.
Results
83b1 showed the significant anti-cancer effects on all ESCC cell lines compared to CDDP;
however, 83b1 revealed much lower toxic effects on non-tumor cell lines than CDDP. The
predicted molecular target of 83b1 is peroxisome proliferator-activated receptor delta
(PPAR), which is a widely known oncoprotein. Additionally the expression of COX-2 mRNA
and COX-2–derived PGE2 were down-regulated by 83b1 in a dose-dependent manner in
ESCC cell lines. Furthermore, 83b1 was shown to significantly reduce the tumor size in nude
mice xenograft.
Conclusion
The results of this study suggest that the potential anti-cancer effects of 83b1 on human
esophageal cancers occur through the possible oncotarget, PPAR, and down-regulation of
the cancer related genes and molecules.
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Introduction
Esophageal cancer is the eighth most prevalent cancer and
the sixth leading cause of cancer deaths throughout the
world [1]. At present, the treatments for esophageal cancers
include surgical resection, radiotherapy and chemotherapy
[2,3]. However, the curative effects of the existing treatments
appear to be insufficient, as reflected by the sub-optimal 
5-year survival rate (almost less than 20%) and the observed
toxicities of the anti-cancer drugs [3,4]. Therefore, identifica-
tion of new anti-cancer drugs for treatment of esophageal
and other cancers has become a crucial issue.
Quinoline derivatives, which have been widely reported
to possess a broad range of pharmaceutical activities, can be
isolated from different plant sources [5]. The first commonly
known natural quinoline compound, 4-hydroxy-6-methoxy-
quinoline-2-carboxylic acid (Fig. 1), was extracted from
Ephedra pachyclada ssp. sinaica, which has been widely used
in traditional herbal medicine against allergy, inflammation,
microbial and cardiovascular diseases, and cancer [6,7]. 
8-Hydroxyquinoline and its derivatives were also reported
as natural products such as those isolated from the roots of
Centaurea diffusa with phytotoxic activities [8] and Suaeda cor-
niculata with anti-bacterial and anti-fungal activities [9].
Therefore, researchers have further improved the efficacy
and potency of quinoline by modifying its structure. Our pre-
vious findings also revealed that the 8-hydroxyquinoline 
derivatives showed relatively promising in vitro and in vivo
anti-cancer effects [5], as well as anti-bacterial effects, imply-
ing the importance of the 8-hydroxyl group for their biolog-
ical actions [10].
Peroxisome proliferator-activated receptor (PPAR), a
member of the nuclear hormone receptor superfamily, exists
as three main subtypes, PPAR, PPAR, and PPAR (also
known as PPAR). These receptors can also act as ligand-
activated transcription factors. PPAR is ubiquitously 
expressed in most human tissues, and many studies have
shown that PPAR is highly overexpressed in tumor cells rel-
ative to non-tumor cells. Moreover, it has been shown to be
involved in cell differentiation and inflammation, which are
highly related to tumor development [11]. In the ligand-
bound state, PPAR can bind to an activator and associate
with the peroxisome proliferated response element to pro-
mote gene transcription. The potential pathways related to
the PPAR for inducing tumor growth include the cyclooxy-
genase 2 (COX-2) [12,13]. It has also been reported that there
are solid correlations among the pathways of PPAR, over-
expression of COX-2 and tumor development [12]. Thus, tar-
geting PPAR forms a very important direction for exploring
novel anti-cancer agents. 
Cyclooxygenase, which is also known as prostaglandin H
synthase, exists as two main isoforms, COX-1 and COX-2.
COX-1 is constitutively expressed in most mammalian cells
and has functions such as regulation of renal blood flow and
platelet aggregation [14]. However, COX-2 is inducible and
usually overexpressed in gastrointestinal cancers, including
esophageal cancer [15,16]. Previous studies showed that
COX-2 is highly related to tumorigenic events involving cell
proliferation, invasion, apoptosis, inflammation and angio-
genesis [17,18]. Moreover, it has been shown that COX-2 
derived prostaglandin E2 (PGE2) is one of the potential prod-
ucts that promotes development of tumors [19]. PGE2 is a
well-known molecule that participates in tumorigenesis by
binding to complementary EP2 and EP4 receptors on cell
membranes [16].
In this study, a novel quinoline derivative (8-(4-(trifluo-
romethyl)benzyloxy)-1,2,3,4-tetrahydro-2-methylquin-oline,
named as 83b1) was examined through in vitro and in vivo
anti-cancer tests on esophageal cancer cell lines. The associ-
ated mechanisms were also investigated based on molecular
docking analysis to reveal PPAR as a target in cancer treat-
ment.
Materials and Methods
1. Reagents and materials
Cell culture medium RPMI-1640, F-12, Dulbecco's modi-
fied Eagle's medium, minimum essential medium  (MEM),
keratinocyte serum-free medium (KSFM), fetal bovine serum
(FBS), and penicillin/streptomycin were purchased from Life
Technologies (Carlsbad, CA). 83b1 was completely dissolved
in dimethylsulfoxide (DMSO). 
MeO
OH
COOHN
Fig. 1. Structure of 4-hydroxy-6-methoxyquinoline-2-car-
boxylic acid.
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2. Synthesis of 83b1 with electrospray ionization mass spec-
trometry and 1H-NMR examination
8-(4-(Trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-
2-methylquinoline (compound 83b1) (Fig. 2) was prepared
according to our previously reported method of asymmetric
hydrogenation on 8-(4-(trifluoromethyl)-benzyloxy)-2-methy-
lquinoline, which was obtained through nucleophilic substi-
tution of commercially available 8-hydroxy-2-methylqui-
noline (Sigma-Aldrich, St. Louis, MO) [20]. The structure and
purity of 83b1 was examined through 1H-NMR and liquid
chromatography mass spectrometry (LC-MS). 
83b1, which appeared as a white solid, was dissolved in
CDCl3 completely and examined by 1H-NMR (Supplemen-
tary Fig. S1). Upon analysis the following spectrum was 
reported: 1H-NMR (500 MHz, CDCl3):  1.30 (d, 3H, J=6.0
Hz), 1.63-1.72 (m, 1H), 1.95-1.98 (m, 1H), 2.75-2.79 (m, 1H),
2.85-2.90 (m, 1H), 3.39-3.43 (m, 1H), 4.17 (bs, 1H), 5.13 (q, 2H,
J=12.5 Hz), 6.54 (t, 1H, J=8.0 Hz), 6.68 (d, 1H, J=8.0 Hz), 6.72
(d, 1H, J=7.5 Hz), 7.55 (d, 2H, J=8.0 Hz), 7.66 (d, 2H, J=8.5
Hz). These findings are consistent with the expected struc-
ture shown in Fig. 2. The purity and molecular weight of the
synthesized 83b1 were further examined by LC-MS (Supple-
mentary Fig. S2). According to the data obtained, there were
three peaks separated in different retention periods. The
peaks were analyzed by electrospray ionization mass spec-
trometry (Supplementary Fig. S3), and the peak comprising
99.7% total area showed a m/z ratio of 83b1 (molecular
weight 321 g/mol), whereas the other two peaks comprising
0.3% total area were found to be impurities. Therefore, the
purity of 83b1 is very high.
3. Cell lines and culture conditions
One of the esophageal squamous cell carcinoma (ESCC)
cell lines of Hong Kong Chinese origin, SLMT-1 [21], was
kindly provided by Professor Gopesh Srivastava of the 
Department of Pathology, the University of Hong Kong. The
other two ESCC cell lines of Hong Kong Chinese origin, 
including HKESC-2 and HKESC-4, and three ESCC cell lines
of Japanese origin, including KYSE-150, KYSE-450, and
KYSE-520 [22], were purchased from DSMZ (Braunschweig,
Germany). Two non-tumor esophageal epithelial cell lines
including NE-1 [23] and NE-3 [24] were kindly provided by
Professor George S. W. Tsao from the Department of
Anatomy, the University of Hong Kong. A human skin cell
line, HEK001, was purchased from the American Type Cul-
ture Collection (ATCC) and cultured as suggested. The cul-
ture medium for KYSE-150 and KYSE-450 was RPMI with
45% F-12 and 10% FBS, that for KYSE-520 was RPMI with
10% FBS, that for SLMT-1, HKESC-2, and HKESC-4 was
MEM with 10% FBS, and NE-1, NE-3, and HEK001 were
cultured on KSFM with complementary supplements. All
media were supplemented with 100 units/mL penicillin G
and 100 µg/mL streptomycin, and all cell lines mentioned
above were cultured at 37°C in a humidified incubator with
5% CO2. 
4. In vitro cytotoxicity studies by MTS
3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was per-
formed to evaluate the growth inhibitory effects of 83b1 on
the six described ESCC cell lines and three immortalized
non-tumor cell lines using the CellTiter96 AQueous One 
Solution (Promega, Madison, WI) for cell proliferation assay
as previously reported [25]. In addition, a widely used anti-
cancer drug, cisplatin (CDDP), was used as a positive control
[26]. Briefly, 5103 cells were seeded onto each well of the 96-
well plate and allowed to grow for 24 hours. After incubation
for 24 hours, different concentrations of 83b1 and CDDP 
(0, 1.5625, 3.125, 6.25, 12.5, 25, and 50 µg/mL) were added as
the treatment. The results were recorded after 72 hours of the
treatments using a micro-plate reader to measure the 
absorbance at 495 nm. 
5. Molecular docking analysis
Evaluation of the possible molecular binding targets of
83b1 was conducted based on the similarity ensemble 
approach (SEA) using the search engine available from
http://sea.bkslab.org. The binding of 83b1 to the protein tar-
gets was predicted based on molecular structures matched
against the ChEMBL medicinal chemistry database version
Ivan Ho Yuen Pun, Anti-cancer Effects of 83b1 on Esophageal Cancer
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Fig. 2. Structure of 83b1.
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Fig. 3.  (A-I) Inhibitory effects of 83b1 on ESCC and non-tumor cell lines examined by MTS cytotoxicity assay. ESCC,
esophageal squamous cell carcinoma; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium. (Continued to the next page)
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12 as previous described [27]. Another docking program 
involving the molecular docking server (http://www.dock-
ingserver.com/web) was used to determine the binding
affinity of 83b1 to its predicted target relative to the natural
ligand of the target. The docking calculations were con-
ducted using DockingServer [28].
6. Reverse transcription polymerase chain reaction and
quantitative real-time polymerase chain reaction 
The gene expression levels of COX-2 in the four ESCC cell
lines (KYSE-150, KYSE-450, SLMT-1, and HKESC-4) with the
treatments of 83b1 were studied by quantitative real-time
polymerase chain reaction (qPCR). Approximately 1106
cells from each cell line were evenly separated into eight
replicates and allowed to seed for 24 hours. Three different
concentrations of 83b1 (5, 10, and 20 µg/mL) and a negative
control (0.05% DMSO) were used to incubate the cells for 24
hours. The total RNA of each the cell line was extracted using
a RNeasy Mini Kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. Two micrograms of extracted
RNA was reverse-transcribed to cDNA using reverse-tran-
scriptase (Promega). 
Two-step reverse transcription polymerase chain reaction
(RT-PCR) assay reagents with SYBR Green (Promega) were
used for the qPCR reactions, which were conducted as fol-
lows: pre-denaturation for 2 minutes at 95°C; polymerase
chain reaction (PCR) amplification for 40 cycles of 15 seconds
at 95°C and 2 minutes at 60°C. The threshold cycle (Ct) was
recorded using a Pikoreal real-time PCR system (Thermo Sci-
Ivan Ho Yuen Pun, Anti-cancer Effects of 83b1 on Esophageal Cancer
M
TS
 re
la
tiv
e 
un
it
150
100
50
0
0
Concentration (µg/mL)
MTS cytotoxicity of 83b1 on KYSE-150
20 40 60
A
CDDP
83b1
M
TS
 re
la
tiv
e 
un
it
150
100
50
0
0
Concentration (µg/mL)
MTS cytotoxicity of 83b1 on KYSE-450
20 40 60
B
CDDP
83b1
M
TS
 re
la
tiv
e 
un
it
150
100
50
0
0
Concentration (µg/mL)
MTS cytotoxicity of 83b1 on KYSE-520
20 40 60
C
CDDP
83b1
M
TS
 re
la
tiv
e 
un
it
150
100
50
0
0
Concentration (µg/mL)
MTS cytotoxicity of 83b1 on SLMT-1
20 40 60
D
CDDP
83b1
M
TS
 re
la
tiv
e 
un
it
150
100
50
0
0
Concentration (µg/mL)
MTS cytotoxicity of 83b1 on HKESC-2
20 40 60
E
CDDP
83b1
M
TS
 re
la
tiv
e 
un
it
150
100
50
0
0
Concentration (µg/mL)
MTS cytotoxicity of 83b1 on HKESC-4
20 40 60
F
CDDP
83b1
M
TS
 re
la
tiv
e 
un
it
150
100
50
0
0
Concentration (µg/mL)
MTS cytotoxicity of 83b1 on NE-1
20 40 60
G
CDDP
83b1
M
TS
 re
la
tiv
e 
un
it
150
100
50
0
0
Concentration (µg/mL)
MTS cytotoxicity of 83b1 on NE-3
20 40 60
H
CDDP
83b1
M
TS
 re
la
tiv
e 
un
it
150
100
50
0
0
Concentration (µg/mL)
MTS cytotoxicity of 83b1 on HEK001
20 40 60
I
CDDP
83b1
Fig. 3. (Continued from the previous page)
VOLUME 49 NUMBER 1 JANUARY 2017  223
entific, Waltham, MA). Glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) was used as an internal control to nor-
malize the quantity of cDNA synthesized from all cell lines.
The specific primers for COX-2 were as follows: 5-CCA GCA
CTT CAC GCA TCA GT-3 (forward) and 5-ACG CTG TCT
AGC CAG AGT TTC AC-3 (reverse) [29] and the specific
primers for GAPDH were as follows: 5-AAA TCA AGT
GGG GCG ATG CTG-3 (forward) and 5-GCA GAG ATG
ATG ACC CTT TTG-3 (reverse) [30].
7. Enzyme-linked immuno-sorbent assay
The effects of 83b1 on the production of PGE2 in the cell
lines (KYSE-150, KYSE-450, and SLMT-1) were examined
using an enzyme-linked immuno-sorbent assay (ELISA) kit
(Cayman, Ann Arbor, MI). Approximately 1106 cells from
each cell line were evenly separated into eight replicates and
then seeded for 24 hours. Three different concentrations of
83b1 (5, 10, and 20 µg/mL) and a negative control (0.05%
DMSO) were used to incubate the cells for 48 hours. The cul-
ture medium was then removed for quantitative determina-
tion of PGE2 with reference to the standard curve according
to the manufacturer’s instructions. 
8. In vivo studies of 83b1 in nude-mice xenograft with
KYSE-450
Athymic nude mice 4 weeks of age were purchased from
the State Key Laboratory of Chinese Medicine and Molecular
Pharmacology (Shenzhen, China), the Hong Kong Polytech-
nic University. All procedures were approved by the ethics
committee. Approximately 5106 KYSE-450 cells were 
injected subcutaneously into the mid-dorsal region of eight
athymic nude mice. Tumors were allowed to grow without
treatment until a volume of 150 mm3 was reached. The ten
nude mice were randomly divided into two groups. 83b1
was then injected into five mice intraperitoneally at 10
mg/kg/day, while the rest of the mice were used as the 
vehicle control. Tumor volumes were measured daily with
calipers and calculated as previously described [25]. 
9. Statistical analyses
All values expressed in the charts are shown as the
mean±standard error of means, and statistical analyses were
conducted using the statistic program Prism ver. 5. A p-value
of < 0.05 was considered statistically significant.
Results
1. In vitro cytotoxicity studies
The inhibitory effects of 83b1 on the described ESCC cell
lines and immortalized non-tumor cell lines were examined
by MTS cytotoxicity assay. As shown in Fig. 3A-F, 83b1
showed comparable inhibitory effect on all ESCC cell lines
with CDDP in a dose-dependent manner. The inhibitory 
effects are summarized in terms of MTS50 (50% reduction of
MTS signals compared with the vehicle control) in Table 1.
In addition, 83b1 showed significantly weaker cytotoxic 
Cancer Res Treat. 2017;49(1):219-229
Table 1. Summary of inhibitory effects (MTS50) of 83b1 on
ESCC and non-tumor cell lines
MTS50 (µg/mL) for 72 hr
83b1 CDDP
ESCC cell line
KYSE-150 11.72 8.58
KYSE-450 9.71 15.85
KYSE-520 12.47 10.08
SLMT-1 5.87 8.99
HKESC-2 5.94 1.98
HKESC-4 6.87 18.81
Non-tumor cell line
NE-1 5.15 1.03
NE-3 > 50 0.02
HEK001 133.30 1.94
ESCC, esophageal squamous cell carcinoma; CDDP, cis-
platin.
Table 2. Two human proteins with the highest ranking for ligand-binding to 83b1
Reference name Species Expected value Maximum target  complementary value
Peroxisome proliferator- Human 4.01e-7 0.36
activated receptor delta
Protein-tyrosine Human 2.38e-8 0.33
phosphatase 1C
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effects on NE-1, NE-3, and HEK001 than CDDP (Table 1, 
Fig. 3G-I). 
2. Molecular docking analysis
The SEA, which has been shown to be an important step
for predicting possible drug target(s), was used to evaluate
possible biological targets of 83b1 in cells [26]. The possible
predicted protein targets with promising ligand-protein
binding are shown in Table 2. These two targets were found
to be complementary to 83b1, with the highest complemen-
tary score based on their molecular structures according to
the ChEMBL medicinal chemistry database indicating that
they are protein-tyrosine phosphatase 1C and PPAR. 
Another docking program in molecular docking server was
utilized to determine the binding affinity of 83b1 to its pre-
dicted target, PPAR (Fig. 4). The free binding energy of 83b1
to PPAR is –7.41 kcal/mol (Fig. 4A), which shows a more
stable and stronger binding than that between PPAR with
its natural ligand, arachidonic acid that the free binding 
energy of arachidonic acid to PPAR was estimated to 
be –5.66 kcal/mol (Fig. 4B).
3. Effects of 83b1 on the mRNA expression of COX-2 in
ESCC cell lines 
Based on the prediction of PPAR as possible targets of
83b1 from the molecular docking analysis, qPCR was con-
ducted to determine the down-regulating effect of 83b1 on
COX-2 mRNA expression in four of the ESCC cell lines
(KYSE-150, KYSE-450, SLMT-1, and HKESC-4). As previ-
ously described, the four ESCC cell lines were seeded for 24
hours and three concentrations of 83b1 (5, 10, and 20 µg/mL)
were used to treat the cells before harvest. RT-PCR was per-
formed to obtain the cDNA for qPCR to determine the 
expression of COX-2 mRNA with specific primers. As shown
in Fig. 5, the expression of COX-2 mRNA in all four ESCC
cell lines was significantly reduced after treatment with 83b1
(p < 0.05, p < 0.01, and p < 0.001 vs. untreated control, n=4).
4. Effects of 83b1 on PGE2 production in ESCC cell lines
ELISA was performed to estimate the suppressing effects
of 83b1 on PGE2 production in the three ESCC cell lines
(KYSE-150, KYSE-450, and SLMT-1). As mentioned above,
the three ESCC cell lines were seeded for 24 hours, then
treated with 83b1 at three different concentrations (5, 10, and
Ivan Ho Yuen Pun, Anti-cancer Effects of 83b1 on Esophageal Cancer
Fig. 4. Molecular docking of 83b1 (A) and arachidonic acid (B) on peroxisome proliferator-activated receptor .
A
B
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20 µg/mL) for 48 hours before the medium was collected for
the assay. As shown in Fig. 6, 83b1 significantly down-regu-
lated the production of PGE2 in all three ESCC cell lines at
the respective doses (p < 0.01, p < 0.001 vs. untreated control,
n=4).
5. In vivo anti-tumor effect of 83b1 on nude-mice xenograft
with KYSE-450
Athymic nude mice xenografted with the human KYSE-
450 ESCC cell line were used to test the in vivo anti-tumor 
effect of 83b1.
As shown in Fig. 7, 83b1 significantly inhibited the tumor
growth in mice when administered at 10 mg/kg/day relative
to the vehicle controls. On day 19, the xenografts of the nude
mice showed a significant reduction in tumor size after daily
treatment with 83b1. Overall, the results showed that 83b1
effectively suppressed tumor growth in vivo (p < 0.001 vs.
control, n=5).
Discussion
Natural compounds have been shown to have great poten-
tial in pharmaceutical applications. The greatest advantage
of these compounds over traditional anti-cancer medicines
is that they show much weaker cytotoxicity against normal
cells because of their target-specificity. Actually, most exist-
ing anti-cancer drugs show very strong inhibitory effects
against different kinds of tumors, but also trigger a series of
side effects, some of which might be severe. Therefore, chem-
ically modified natural compounds show great potential for
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Fig. 5. The down-regulating effects of 83b1 on cyclooxygenase 2 (COX-2) mRNA expression in KYSE-150 (A), KYSE-450 (B),
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use in disease therapies. Chemically modified quinoline-
derivatives have wide pharmaceutical power as therapeutic
agents, and 83b1 is a quinoline-derivative that has been
shown to exert significant anti-tumor effects against ESCC
with low cytotoxicity toward non-tumor cells. 
In this study, 83b1 showed significantly greater anti-tumor
effects against a series of ESCC cell lines relative to the
widely used anti-cancer drug, CDDP, with much lower 
cytotoxicity against nontumor cells. It is an important crite-
rion that anti-cancer drugs are able to suppress cancer
growth selectively while they are not provoking damaging
effects on normal cells.
Possible targets of 83b1 were determined by molecular
docking analysis, which revealed that it has a high binding
preference to compete with the natural ligand to target
PPAR, which has been known as an oncoprotein. The func-
tions of PPAR in COX-2 and COX-2–derived PGE2 produc-
tion have been described, and the involvement of COX-2 and
PGE2 in tumorigenesis in the ESCCs has been widely 
reported in many studies. Accordingly, it is important to see
the effects of 83b1 on the production of COX-2 and COX2–
derived PGE2.
Our results showed that 83b1 can significantly down-reg-
ulate COX-2 mRNA expression in ESCC cell lines. Moreover,
the production of COX-2–derived PGE2 in ESCC cell lines
was also significantly reduced by treatment with 83b1.
Therefore, it is possible that 83b1 can antagonize its possible
target PPAR and hence suppress cancer growth through
down-regulation of COX-2 and PGE2 production. The in vivo
study also showed that 83b1 can significantly suppress 
tumors in animals within 19 days, and that tumors inside of
nude mice almost disappeared. 
Overall, this study comprehensively described the func-
tions and effects of 83b1 on ESCC cell lines. The findings of
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this study also revealed the potential use of chemically mod-
ified natural compounds in disease therapy.
Conclusion
Chemically modified quinoline derivatives were recently
shown to inhibit tumor growth through different kinds of
mechanisms by interacting with various targets [5,10]. Here,
we demonstrated that a novel quinoline derivative, 83b1, has
strong inhibitory effects on tumor growth with less toxicity
in non-tumor cell lines and nude mice xenograft models. The
predicted target PPAR of 83b1 has been widely reported as
a cancer-promoting protein ubiquitously overexpressed in
different types of cancer tissues [26]. We found that 83b1 can
target PPAR, resulting in downregulation of COX-2 mRNA
expression and reduced production of PGE2. The results pre-
sented herein will greatly advance development of novel
drugs for cancer therapy by targeting PPAR.
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